| Chen, Zhendong |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor |
|
|
| Recruiting | 2 | 200 | RoW | TQ-B3101 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 03/21 | 09/21 | | |
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 196 | RoW | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer | 12/21 | 04/22 | | |
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. |
|
|
| Completed | 2 | 34 | RoW | Chidamide, CS055, Envafolimab, KN035 | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 02/23 | 05/24 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 222 | RoW | SHR-1701, Famitinib | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 12/22 | 10/23 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
